Enlightenment through smart measurements

Open menu

News & Events

OPSENS REPORTS Q4 and FY2018 RESULTS – RECORD ANNUAL REVENUE SURPASS $24 M AND RECORD QUARTERLY FFR REVENUES AT $4.1 M

28 November 2018

Quebec City, Quebec, November 28, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the fourth quarter and fiscal year ended August 31, 2018. Highlights for the quarter and for the year Fractional Flow Reserve (“FFR”) revenues reach $4.1 M in the fourth quarter of 2018 compared with $2.8…

Read more

OPSENS RECEIVES HEALTH CANADA APPROVAL FOR dPR INTENDED FOR THE DIAGNOSIS OF CORONARY STENOSIS WITH THE HEART AT REST

27 November 2018

Quebec City, Quebec, November 27, 2018 – Opsens Inc. (“Opsens”) (TSX:OPS) (OTCQX:OPSSF)  announced today that it has obtained approval from Health Canada to market its dPR Proprietary Resting Index,  which measures intracoronary pressure and establishes a diagnosis with the heart at rest to guide the treatment of patients with coronary heart disease. dPR stands for Diastolic…

Read more

OPSENS – FIRST USE OF dPR FOR THE DIAGNOSIS OF CORONARY STENOSIS WITH THE HEART AT REST

8 November 2018

Quebec City, Quebec, November 8, 2018 – Opsens Inc. (“Opsens”) (TSX:OPS) (OTCQX:OPSSF) announces that its Diastolic Pressure Ratio called dPR, has been used for the first time by Dr. Hitoshi Matsuo, cardiologist and President of the Gifu Heart Center Japan. The measurement of Fractional Flow Reserve (“FFR”) as a method of assessing intracoronary pressure has gained credibility and popularity…

Read more

OPSENS – 50,000 PATIENTS DIAGNOSED WITH THE OPTOWIRE

1 November 2018

Quebec City, Quebec, November 1st, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) has reached an important milestone with more than 50,000 patients assessed with the OptoWire™, a pressure guidewire used to measure Fractional Flow Reserve (“FFR”) to diagnose and treat cardio vascular disease. The use of pressure guidewires to measure FFR for…

Read more

OPSENS TO HOST INVESTOR WEBINAR ON THURSDAY, OCTOBER 4 TO PROVIDE UPDATE ON RECENT DEVELOPMENTS

3 October 2018

OPSENS TO HOST INVESTOR WEBINAR ON THURSDAY, OCTOBER 4 TO PROVIDE UPDATE ON RECENT DEVELOPMENTS Quebec City, Quebec, October 3, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) will host an investor webinar and live Q&A session on Thursday, October 4, 2018, at 4.05 p.m. EST. The webinar will feature a presentation by…

Read more

Opsens Solutions present at the ESREF 2018

28 September 2018

We are going to be happy to meet you at booth 21 – ESREF 2018 – the 29th European Symposium on Reliability of Electron Devices, Failure Physics and Analysis, October 1-5, 2018, at Aalborg, Denmark.

OPSENS – NEW PRODUCT FOR THE DIAGNOSIS OF CORONARY STENOSIS WITH THE HEART AT REST

20 September 2018

Quebec City, Quebec, September 20, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) announces it has developed a product that will allow the diagnosis of coronary heart blockages with the heart at rest. Filing for regulatory approvals has been completed in targeted territories. Opsens plans to begin commercialization by the end of calendar…

Read more

OPSENS REPORTS Q3 2018 RESULTS – Quarterly Revenues Eclipse $6.4 M

12 July 2018

Quebec City, Quebec, July 12, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the third quarter ended May 31, 2018. Highlights for the quarter Consolidated revenues reached $6,398,000 for the three-month period compared with $4,892,000 for the same period last year, an increase of $1,506,000 or 31%; Consolidated…

Read more

Opsens Solutions have moved in a new improved facilities

30 April 2018

Opsens Solutions is proud to inform that we have moved to a new improved facilities. Our new address is: 319 Franquet Street, Suite 110, Québec City, QC G1P 4R4 Canada. Phone number haven’t change: 418-682-9996 www.opsens-solutions.com

OPSENS APPLAUDS JAPANESE GOVERNMENT NEW REGULATION SUPPORTING DIAGNOSIS, SUCH AS FFR, BEFORE TREATMENT OF CORONARY STENOSIS

24 April 2018

Quebec City, Quebec, April 24, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) applauds Japan’s Ministry of Health, Labor and Welfare (“MHLW”) on its new regulation requiring the evaluation of any coronary stenosis prior to its treatment, specifically mentioning Fractional Flow Reserve (“FFR”) as a preferred assessment method. The MHLW recently revised medical…

Read more